PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce & Industry, Govt., of India)

New cases at US Federal Circuit as on 19th March, 2012					
NAME	**DOCKET**	**SRCE**	**NUMBER**	**DKTD**	**NOS**
3M Company	2012-1241	DCT	09-CV-03335	3/2/2012	830
3M Innovative Properties	2012-1241	DCT	09-CV-03335	3/2/2012	830
Abbott Cardiovascular Systems	2012-1223	DCT	08-CV-0230	2/24/2012	830
Abbott Cardiovascular Systems	2012-1224	DCT	08-CV-1021	2/24/2012	830
Abbott Laboratories	2012-1223	DCT	08-CV-0230	2/24/2012	830
Abbott Laboratories	2012-1224	DCT	08-CV-1021	2/24/2012	830
Abbott Laboratories	2012-1244	DCT	11-MC-0042	3/5/2012	
Abbott Laboratories, Inc.	2012-1223	DCT	08-CV-0230	2/24/2012	830
Accord Healthcare Inc.	2012-1195	DCT	11-CV-1192	2/7/2012	830
Acella Pharmaceuticals, LLC	2012-1106	DCT	10-CV-1780	12/16/2011	830
Amphastar Pharmaceuticals, Inc	2012-1103	DCT	11-CV-11681	12/13/2011	830
Amphastar Pharmaceuticals, Inc	2012-1104	DCT	11-CV-11681	12/13/2011	830
Andrx Pharmaceuticals L.L.C.	2012-1118	DCT	09-CV-0037	12/28/2011	830
Andrx Pharmaceuticals L.L.C.	2012-1228	DCT	09-CV-0037	2/27/2012	830
Andrx Pharmaceuticals, Inc.	2012-1118	DCT	09-CV-0037	12/28/2011	830
Andrx Pharmaceuticals, Inc.	2012-1228	DCT	09-CV-0037	2/27/2012	830
Apotex Corp.	2012-1179	DCT	07-CV-0779	2/1/2012	830
Apotex, Inc.	2012-1179	DCT	07-CV-0779	2/1/2012	830
Bayer Healthcare, LLC	2012-1243	DCT	11-CV-5603	3/2/2012	830
Bayer S.A.S.	2012-1206	DCT	10-CV-0276	2/13/2012	830
Classen Immunotherapies, Inc.	2012-1141	PTO	90/007,638	1/10/2012	
Glaxo Group Limited	2012-1120	DCT	10-CV-0608	12/28/2011	830
GlaxoSmithKline LLC	2012-1120	DCT	10-CV-0608	12/28/2011	830
Hoffmann-La Roche Inc.	2012-1131	DCT	09-CV-5283	1/3/2012	830
Hoffmann-La Roche Inc.	2012-1132	DCT	09-CV-6335	1/3/2012	830
Hoffmann-La Roche Inc.	2012-1195	DCT	11-CV-1192	2/7/2012	830
Intas Pharmaceutical Ltd.	2012-1195	DCT	11-CV-1192	2/7/2012	830
Lupin Pharmaceuticals, Inc.	2012-1118	DCT	09-CV-0037	12/28/2011	830
Lupin Pharmaceuticals, Inc.	2012-1228	DCT	09-CV-0037	2/27/2012	830
Lupin, Ltd.	2012-1118	DCT	09-CV-0037	12/28/2011	830
Lupin, Ltd.	2012-1228	DCT	09-CV-0037	2/27/2012	830
Momenta Pharmaceuticals, Inc.	2012-1103	DCT	11-CV-11681	12/13/2011	830
Momenta Pharmaceuticals, Inc.	2012-1104	DCT	11-CV-11681	12/13/2011	830
Mylan Pharmaceuticals Inc.	2012-1118	DCT	09-CV-0037	12/28/2011	830
Mylan Pharmaceuticals Inc.	2012-1228	DCT	09-CV-0037	2/27/2012	830
Novartis Consumer Health, Inc.	2012-1243	DCT	11-CV-5603	3/2/2012	830
Novozymes A/S	2012-1138	DCT	10-CV-0251	1/10/2012	830

H.O.: 101, Aditya Trade Centre, Ameerpet, Hyderabad – 500038
Tel: 040-23735462/23735466, Fax: 91-40-23735464
Email: info@pharmexcil.com, patents@pharmexcil.com

Novozymes North America, Inc.	2012-1138	DCT	10-CV-0251	1/10/2012	830
Onco Therapies Limited	2012-1151	DCT	11-CV-1121	1/12/2012	830
Procter & Gamble Co., The	2012-1243	DCT	11-CV-5603	3/2/2012	830
Sandoz, Inc.	2012-1103	DCT	11-CV-11681	12/13/2011	830
Sandoz, Inc.	2012-1104	DCT	11-CV-11681	12/13/2011	830
Sanofi-Aventis U.S. LLC	2012-1151	DCT	11-CV-1121	1/12/2012	830
Senju Pharmaceutical Co., Ltd.	2012-1179	DCT	07-CV-0779	2/1/2012	830
Spectrum Healthcare Resources,	2012-5037	CFC	11-CV-570	1/5/2012	140
Teva Pharmaceutical Industries	2012-1131	DCT	09-CV-5283	1/3/2012	830
Teva Pharmaceuticals USA, Inc.	2012-1131	DCT	09-CV-5283	1/3/2012	830
Watson Laboratories, Inc. -	2012-1117	DCT	10-CV-20526	12/27/2011	830
Watson Laboratories, Inc. -	2012-1202	DCT	10-CV-20526	2/9/2012	830
Watson Pharma, Inc.	2012-1103	DCT	11-CV-11681	12/13/2011	830
Watson Pharma, Inc.	2012-1104	DCT	11-CV-11681	12/13/2011	830
Watson Pharma, Inc.	2012-1117	DCT	10-CV-20526	12/27/2011	830
Watson Pharma, Inc.	2012-1202	DCT	10-CV-20526	2/9/2012	830
Watson Pharmaceuticals, Inc.	2012-1103	DCT	11-CV-11681	12/13/2011	830
Watson Pharmaceuticals, Inc.	2012-1104	DCT	11-CV-11681	12/13/2011	830
Watson Pharmaceuticals, Inc.	2012-1117	DCT	10-CV-20526	12/27/2011	830
Watson Pharmaceuticals, Inc.	2012-1202	DCT	10-CV-20526	2/9/2012	830